- Home
- BLUWW vs DRMA Comparison
BLUWW vs DRMA Comparison
Compare BLUWW & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLUWW | DRMA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLUWW | DRMA |
|---|---|---|
| Price | $0.70 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | N/A | ★ 102.5K |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $2.34 |
| 52 Week High | N/A | $23.70 |
Technical Indicators
Market Signals| Indicator | BLUWW | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.67 |
| Support Level | N/A | $2.66 |
| Resistance Level | N/A | $2.98 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 35.37 |
Price Performance
Historical ComparisonAbout DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.